- Home
- DXC vs ENOV Comparison
DXC vs ENOV Comparison
Compare DXC & ENOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DXC
- ENOV
- Stock Information
- Founded
- DXC 1959
- ENOV 1995
- Country
- DXC United States
- ENOV United States
- Employees
- DXC N/A
- ENOV N/A
- Industry
- DXC EDP Services
- ENOV Fluid Controls
- Sector
- DXC Technology
- ENOV Industrials
- Exchange
- DXC Nasdaq
- ENOV Nasdaq
- Market Cap
- DXC 2.5B
- ENOV 2.1B
- IPO Year
- DXC N/A
- ENOV 2008
- Fundamental
- Price
- DXC $16.26
- ENOV $33.06
- Analyst Decision
- DXC Hold
- ENOV Buy
- Analyst Count
- DXC 7
- ENOV 4
- Target Price
- DXC $20.29
- ENOV $55.00
- AVG Volume (30 Days)
- DXC 1.1M
- ENOV 1.0M
- Earning Date
- DXC 05-14-2025
- ENOV 05-08-2025
- Dividend Yield
- DXC N/A
- ENOV N/A
- EPS Growth
- DXC N/A
- ENOV N/A
- EPS
- DXC N/A
- ENOV N/A
- Revenue
- DXC $13,088,000,000.00
- ENOV $2,150,191,000.00
- Revenue This Year
- DXC N/A
- ENOV $7.13
- Revenue Next Year
- DXC N/A
- ENOV $6.33
- P/E Ratio
- DXC N/A
- ENOV N/A
- Revenue Growth
- DXC N/A
- ENOV 18.32
- 52 Week Low
- DXC $13.44
- ENOV $29.32
- 52 Week High
- DXC $24.83
- ENOV $53.84
- Technical
- Relative Strength Index (RSI)
- DXC 55.55
- ENOV 41.57
- Support Level
- DXC $15.19
- ENOV $30.65
- Resistance Level
- DXC $16.30
- ENOV $35.62
- Average True Range (ATR)
- DXC 0.45
- ENOV 1.30
- MACD
- DXC 0.20
- ENOV 0.12
- Stochastic Oscillator
- DXC 98.16
- ENOV 48.29
About DXC DXC Technology Company
DXC Technology Co is a vendor-independent IT services provider. The company's operating segment includes Global Business Services (GBS) and Global Infrastructure Services (GIS). It generates maximum revenue from the GIS segment. GIS offerings include Cloud and Security; IT Outsourcing and Modern Workplace. Geographically, it derives a majority of revenue from the Other Europe region.
About ENOV Enovis Corporation
Enovis Corp is a medical technology company that offers medical devices and services across the continuum of patient care, from injury prevention to joint replacement to rehabilitation after surgery, injury, or degenerative disease. Its reportable segments are Prevention & Recovery (P&R) and Reconstructive (Recon). The company generates the maximum revenue from the Prevention & Recovery segment, which includes products that are used to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports-related injuries. The Reconstructive segment provides a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and surgical productivity tools. Geographically, it derives key revenue from the U.S.